JP2025509266A5 - - Google Patents

Info

Publication number
JP2025509266A5
JP2025509266A5 JP2024553327A JP2024553327A JP2025509266A5 JP 2025509266 A5 JP2025509266 A5 JP 2025509266A5 JP 2024553327 A JP2024553327 A JP 2024553327A JP 2024553327 A JP2024553327 A JP 2024553327A JP 2025509266 A5 JP2025509266 A5 JP 2025509266A5
Authority
JP
Japan
Prior art keywords
her2
cancer
antibody
targeted
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509266A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/063852 external-priority patent/WO2023172906A1/en
Publication of JP2025509266A publication Critical patent/JP2025509266A/ja
Publication of JP2025509266A5 publication Critical patent/JP2025509266A5/ja
Pending legal-status Critical Current

Links

JP2024553327A 2022-03-07 2023-03-07 Stingアゴニストを含む抗体薬物コンジュゲート、組み合わせ、および使用方法 Pending JP2025509266A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263317472P 2022-03-07 2022-03-07
US63/317,472 2022-03-07
US202263329680P 2022-04-11 2022-04-11
US63/329,680 2022-04-11
PCT/US2023/063852 WO2023172906A1 (en) 2022-03-07 2023-03-07 Antibody drug conjugates comprising sting agonists, combinations and methods of use

Publications (2)

Publication Number Publication Date
JP2025509266A JP2025509266A (ja) 2025-04-11
JP2025509266A5 true JP2025509266A5 (cg-RX-API-DMAC7.html) 2026-03-13

Family

ID=85800735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553327A Pending JP2025509266A (ja) 2022-03-07 2023-03-07 Stingアゴニストを含む抗体薬物コンジュゲート、組み合わせ、および使用方法

Country Status (11)

Country Link
US (1) US20230398229A1 (cg-RX-API-DMAC7.html)
EP (1) EP4489789A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025509266A (cg-RX-API-DMAC7.html)
KR (1) KR20240150805A (cg-RX-API-DMAC7.html)
CN (1) CN119173277A (cg-RX-API-DMAC7.html)
AU (1) AU2023232820A1 (cg-RX-API-DMAC7.html)
CA (1) CA3245425A1 (cg-RX-API-DMAC7.html)
IL (1) IL315064A (cg-RX-API-DMAC7.html)
MX (1) MX2024010916A (cg-RX-API-DMAC7.html)
TW (1) TW202400241A (cg-RX-API-DMAC7.html)
WO (1) WO2023172906A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116196435B (zh) 2020-04-02 2025-12-02 梅尔莎纳医疗公司 包含sting激动剂的抗体药物缀合物
WO2024192017A1 (en) * 2023-03-13 2024-09-19 Mersana Therapeutics, Inc. Antibody drug conjugates comprising sting agonists, combinations and methods of use
TW202545568A (zh) 2024-01-29 2025-12-01 日商第一三共股份有限公司 抗her2抗體-藥物結合物與其他劑之組合
WO2026043823A2 (en) * 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗her2表位之單株抗體及其使用之方法
CA2964155A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
TW201834697A (zh) * 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體-藥物結合物之組合療法
CA3159770A1 (en) * 2019-11-15 2021-05-20 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
CN116196435B (zh) * 2020-04-02 2025-12-02 梅尔莎纳医疗公司 包含sting激动剂的抗体药物缀合物

Similar Documents

Publication Publication Date Title
CN102812045B (zh) 用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法
HRP20240626T1 (hr) Bispecifična antitijela protiv ceacam5 i cd3
RU2018124319A (ru) Новые антитела к клаудину и способы их применения
JP2022538237A (ja) B細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療
JP2022548947A5 (cg-RX-API-DMAC7.html)
JP2017514795A5 (cg-RX-API-DMAC7.html)
JP2020516240A5 (cg-RX-API-DMAC7.html)
JP2018505177A5 (cg-RX-API-DMAC7.html)
JP2023507190A5 (cg-RX-API-DMAC7.html)
JP2013510868A5 (cg-RX-API-DMAC7.html)
JP2014509593A5 (cg-RX-API-DMAC7.html)
JP2017514461A5 (cg-RX-API-DMAC7.html)
JP2021531732A5 (cg-RX-API-DMAC7.html)
JP2024546605A5 (cg-RX-API-DMAC7.html)
US20250282875A1 (en) Methods of treating colorectal cancer using an anti-ctla4 antibody
WO2023172906A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
JP2023510199A5 (cg-RX-API-DMAC7.html)
JP2024518536A5 (cg-RX-API-DMAC7.html)
CA3099406A1 (en) Antibodies against lif and dosage forms thereof
CN114450025A (zh) 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症
CN114729054A (zh) 使用免疫检查点抑制剂抗体治疗癌症的方法和组合
JP2023103352A5 (cg-RX-API-DMAC7.html)
JPWO2021251459A5 (cg-RX-API-DMAC7.html)
JP2022530272A5 (cg-RX-API-DMAC7.html)
JP2015518824A5 (cg-RX-API-DMAC7.html)